Austin Lebron Albright, MD | |
6360 S 3000 E Ste 200, Salt Lake City, UT 84121-6925 | |
(801) 797-8000 | |
(855) 769-3885 |
Full Name | Austin Lebron Albright |
---|---|
Gender | Male |
Speciality | Physical Medicine And Rehabilitation |
Experience | 10 Years |
Location | 6360 S 3000 E Ste 200, Salt Lake City, Utah |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1194144329 | NPI | - | NPPES |
Facility Name | Location | Facility Type |
---|---|---|
Harris Regional Hospital | Sylva, NC | Hospital |
Dlp Swain County Hospital Llc | Bryson city, NC | Hospital |
Haywood Regional Medical Center | Clyde, NC | Hospital |
Murphy Medical Center Inc | Murphy, NC | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Dlp Western Carolina Physician Practices Llc | 9032338975 | 112 |
News Archive
In response to continued discussion on the validity of the conclusions of the EXCEL trial comparing coronary stenting to coronary bypass surgery, The American Association for Thoracic Surgery (AATS) has released a statement calling for the release of all trial data to help surgeons and patients make informed choices based on sound analysis.
Universal Biosensors announced today that it has agreed amendments to its arrangements with Siemens Healthcare Diagnostics Inc. The parties have agreed to shift the focus of their joint product development activities, provide prepayment of milestones to UBI and improved strip pricing to support Siemens' entry into the point-of-care PT-INR testing market.
Cardiac Dimensions, Inc. today announced that it has initiated its commercial efforts in Europe, treating the first patients with its CARILLON Mitral Contour System under its Conformite Europeenne (CE) Mark approval.
Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.
› Verified 1 days ago
Entity Name | Henderson County Hospital Corporation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1447444559 PECOS PAC ID: 8123938115 Enrollment ID: O20040611001396 |
News Archive
In response to continued discussion on the validity of the conclusions of the EXCEL trial comparing coronary stenting to coronary bypass surgery, The American Association for Thoracic Surgery (AATS) has released a statement calling for the release of all trial data to help surgeons and patients make informed choices based on sound analysis.
Universal Biosensors announced today that it has agreed amendments to its arrangements with Siemens Healthcare Diagnostics Inc. The parties have agreed to shift the focus of their joint product development activities, provide prepayment of milestones to UBI and improved strip pricing to support Siemens' entry into the point-of-care PT-INR testing market.
Cardiac Dimensions, Inc. today announced that it has initiated its commercial efforts in Europe, treating the first patients with its CARILLON Mitral Contour System under its Conformite Europeenne (CE) Mark approval.
Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.
› Verified 1 days ago
Entity Name | Dlp Western Carolina Physician Practices Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1609281641 PECOS PAC ID: 9032338975 Enrollment ID: O20140908002531 |
News Archive
In response to continued discussion on the validity of the conclusions of the EXCEL trial comparing coronary stenting to coronary bypass surgery, The American Association for Thoracic Surgery (AATS) has released a statement calling for the release of all trial data to help surgeons and patients make informed choices based on sound analysis.
Universal Biosensors announced today that it has agreed amendments to its arrangements with Siemens Healthcare Diagnostics Inc. The parties have agreed to shift the focus of their joint product development activities, provide prepayment of milestones to UBI and improved strip pricing to support Siemens' entry into the point-of-care PT-INR testing market.
Cardiac Dimensions, Inc. today announced that it has initiated its commercial efforts in Europe, treating the first patients with its CARILLON Mitral Contour System under its Conformite Europeenne (CE) Mark approval.
Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.
› Verified 1 days ago
Entity Name | Comprehensive Pain Consultants Of The Carolinas Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1558817932 PECOS PAC ID: 5597033076 Enrollment ID: O20170626001487 |
News Archive
In response to continued discussion on the validity of the conclusions of the EXCEL trial comparing coronary stenting to coronary bypass surgery, The American Association for Thoracic Surgery (AATS) has released a statement calling for the release of all trial data to help surgeons and patients make informed choices based on sound analysis.
Universal Biosensors announced today that it has agreed amendments to its arrangements with Siemens Healthcare Diagnostics Inc. The parties have agreed to shift the focus of their joint product development activities, provide prepayment of milestones to UBI and improved strip pricing to support Siemens' entry into the point-of-care PT-INR testing market.
Cardiac Dimensions, Inc. today announced that it has initiated its commercial efforts in Europe, treating the first patients with its CARILLON Mitral Contour System under its Conformite Europeenne (CE) Mark approval.
Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Austin Lebron Albright, MD 800 N Justice St, Hendersonville, NC 28791-3410 Ph: (828) 694-8350 | Austin Lebron Albright, MD 6360 S 3000 E Ste 200, Salt Lake City, UT 84121-6925 Ph: (801) 797-8000 |
News Archive
In response to continued discussion on the validity of the conclusions of the EXCEL trial comparing coronary stenting to coronary bypass surgery, The American Association for Thoracic Surgery (AATS) has released a statement calling for the release of all trial data to help surgeons and patients make informed choices based on sound analysis.
Universal Biosensors announced today that it has agreed amendments to its arrangements with Siemens Healthcare Diagnostics Inc. The parties have agreed to shift the focus of their joint product development activities, provide prepayment of milestones to UBI and improved strip pricing to support Siemens' entry into the point-of-care PT-INR testing market.
Cardiac Dimensions, Inc. today announced that it has initiated its commercial efforts in Europe, treating the first patients with its CARILLON Mitral Contour System under its Conformite Europeenne (CE) Mark approval.
Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.
› Verified 1 days ago
James Tran, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: Rehab 85 N Medical Drive Rm 2122, Salt Lake City, UT 84132 Phone: 801-585-2589 | |
Dr. Chase K Hansen, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1121 E Brickyard Rd Apt 1803, Salt Lake City, UT 84106 Phone: 801-309-0848 | |
Michael Tobler, Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 6360 S 3000 E Ste 300, Salt Lake City, UT 84121 Phone: 385-900-5094 | |
Dr. Jeffrey G Randle, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1160 E 3900 S, #5000, Salt Lake City, UT 84124 Phone: 801-262-8486 Fax: 801-284-8699 | |
Dr. Michael Matthew Green, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 81 N Mario Capecchi Dr, Department Of Pediatrics, Salt Lake City, UT 84113 Phone: 801-213-7737 Fax: 801-587-7539 | |
Ms. Allison Oki, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 50 N Medical Dr, Univerisity Of Utah, Department Of Pm&r, Salt Lake City, UT 84132 Phone: 801-585-2589 Fax: 801-587-7287 | |
Bradeigh Smithson Godfrey, D.O. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 258 Heritage Ctr, Salt Lake City, UT 84112 Phone: 801-587-1290 |